📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-11 18:41
333 analysed today
FollowTelegram
333
Today
150,772
All-time analysed
43,178
Positive
6,703
Negative
92,118
Neutral
8,705
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
9 announcements match the current filters (relevance ≥ 5).
Sandu Pharma Q1 Net Profit Flat at Rs 0.23 Cr; Material Related Party Transactions Proposed
Sandu Pharmaceuticals reported a flat year-on-year performance for Q1 FY27, with revenue from operations at Rs 16.39 Cr compared to Rs 16.70 Cr in the previous year. Net profit remained stable at Rs 0.23 Cr, while EPS improved slightly to Rs 0.37 from Rs 0.23 YoY. The board has recommended the continuation of material related party transactions with Sandu Brothers Private Limited, pending shareholder approval at the AGM on September 11, 2026. A record date of September 4, 2026, has been set for the FY26 dividend eligibility.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results and announced the schedule for its 41st Annual General Meeting and dividend record date.
Why it mattersFor a micro-cap company with a Rs 38 Cr market cap, the continuation of material related party transactions with promoter-linked entities is a key governance factor for investors to monitor.
Q1 Revenue: Rs 16.39 CrQ1 Net Profit: Rs 0.23 CrDividend Record Date: September 4, 2026Q1 Revenue vs TTM Revenue: 24.4%Promoter Holding: 37.79%
📅 Short termThe stock is likely to remain neutral as earnings were flat; however, the upcoming dividend record date in early September may provide minor support.
📈 Long termLimited structural change expected as the company continues to operate with thin margins in a single segment; governance regarding related party transactions remains the primary long-term watch point.
⚠ Risk flags
- Material related party transactions with Sandu Brothers Private Limited
- Low operating profit margin of 4.1%
- Recent decline in promoter holding from 42.9% to 37.8%
Key Highlights
Revenue from operations for Q1 FY27 stood at Rs 16.39 Cr, a marginal decline of 1.8% compared to Rs 16.70 Cr in Q1 FY26.
Net profit for the quarter was Rs 0.23 Cr, showing minimal change from the Rs 0.22 Cr reported in the same period last year.
Record date for the FY26 dividend is fixed for September 4, 2026, with the AGM scheduled for September 11, 2026.
Proposed appointment of M/s. Dave & Dave as Statutory Auditors for a 5-year term starting from the conclusion of the upcoming AGM.
Board recommended shareholder approval for material related party transactions with M/s. Sandu Brothers Private Limited.
👀 What to Watch
Monitor the shareholder voting outcome regarding the material related party transactions at the AGM and track if the company can improve its low operating margins (4.1%) in upcoming quarters.
Sandu Pharmaceuticals Q1 Revenue at Rs 16.39 Cr; Appoints New Statutory Auditor
Sandu Pharmaceuticals reported a flat Q1 FY27 with revenue of Rs 16.39 Cr, a marginal 1.8% decline from Rs 16.70 Cr in the same quarter last year. Net profit remained stable at Rs 0.23 Cr, matching the previous year's performance. The board has recommended the appointment of M/s Dave & Dave as statutory auditors for a five-year term (FY27-FY31). Additionally, the company set September 4, 2026, as the record date for the FY26 dividend and is seeking shareholder approval for material related-party transactions with Sandu Brothers Private Limited.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and initiated a change in statutory auditors for a new five-year term.
Why it mattersWhile the company remains debt-free, the stagnant revenue and profit growth in a micro-cap (Rs 38 Cr) context suggest limited immediate catalysts for re-rating.
Q1 FY27 Revenue: Rs 16.39 CrQ1 FY27 PAT: Rs 0.23 CrTTM Revenue: Rs 67 CrMarket Cap: Rs 38 CrDividend Record Date: September 4, 2026
📅 Short termNeutral impact expected as earnings are flat; the stock may see minor activity around the dividend record date in early September.
📈 Long termLimited structural change; the company maintains a clean balance sheet but requires significant revenue scaling to impact its valuation significantly.
⚠ Risk flags
- Stagnant revenue growth
- Material related-party transactions with promoter-linked entities
- Low promoter holding at 37.8%
Key Highlights
Q1 FY27 Revenue reported at Rs 16.39 Cr, down 1.8% from Rs 16.70 Cr YoY
Net Profit for the quarter ended June 2026 stood at Rs 0.23 Cr, identical to Q1 FY26
Appointment of M/s Dave & Dave as Statutory Auditors for a 5-year term starting FY27
Record date for FY26 dividend eligibility set for September 4, 2026
Total expenses for the quarter were Rs 16.05 Cr, slightly lower than Rs 16.38 Cr in the year-ago period
👀 What to Watch
Monitor the approval of material related-party transactions at the AGM on September 11, 2026, and observe if the company can break out of its stagnant revenue range in upcoming quarters.
Sandu Pharmaceuticals Q1 Net Profit Flat at ‡0.23 Cr; Sets Sept 4 as Dividend Record Date
Sandu Pharmaceuticals reported a stagnant performance for Q1 FY27, with net profit remaining flat at ‡0.23 crore compared to the previous year. Revenue from operations saw a marginal decline of 1.8% year-on-year to ‡16.39 crore. The company has scheduled its 41st Annual General Meeting for September 11, 2026, and fixed September 4, 2026, as the record date for the proposed dividend. Additionally, the board has recommended the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term.
Confidence: HIGH
What changedThe company has reported its first-quarter results for FY27 and established the timeline for its annual shareholder meeting and dividend distribution.
Why it mattersThe results indicate a period of stagnant growth for the micro-cap pharmaceutical firm, with both top-line and bottom-line figures showing minimal movement compared to the previous year.
Revenue (Q1 FY27): ‡16.39 CrNet Profit (Q1 FY27): ‡0.23 CrEPS (Q1 FY27): ‡0.37Revenue vs TTM Revenue: ~24.4%Record Date: Sept 4, 2026
📅 Short termNeutral. The stock may see minor activity around the dividend record date, but the flat earnings performance is unlikely to trigger a significant re-rating.
📈 Long termLimited. The company continues to operate at a small scale with low margins and stagnant revenue growth, requiring a significant operational shift to attract long-term interest.
⚠ Risk flags
- Low operating margins (4.1%)
- Material related-party transactions with promoter-linked entities
- Stagnant revenue growth
Key Highlights
Revenue from operations stood at ‡16.39 crore for Q1 FY27, down from ‡16.70 crore in Q1 FY26.
Net profit for the quarter was ‡0.23 crore (reported as ‡22.83 lakhs), nearly identical to ‡22.33 lakhs in the year-ago period.
Record date for determining dividend eligibility is fixed as Friday, September 4, 2026.
Total expenses for the quarter were ‡16.05 crore, slightly lower than ‡16.38 crore in the corresponding quarter last year.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors for a 5-year term until 2031.
👀 What to Watch
Investors should monitor the upcoming AGM on September 11 for details on the 'Material Related Party Transactions' with Sandu Brothers Pvt Ltd and any management commentary on improving the low operating margins (currently ~4%).
Sandu Pharma Q1 Revenue at ₹16.39 Cr; Dividend Record Date Set for Sept 4, 2026
Sandu Pharmaceuticals reported a flat Q1 FY27 with revenue of ₹16.39 cr, compared to ₹16.70 cr in the same quarter last year. Net profit for the quarter stood at ₹0.23 cr, showing marginal growth in EPS to 0.37 from 0.23 YoY. The board has fixed September 4, 2026, as the record date for the FY26 dividend. Additionally, a new statutory auditor, M/s. Dave & Dave, has been recommended for a five-year term starting from the upcoming AGM on September 11, 2026.
Confidence: HIGH
What changedThe company has released its Q1 FY27 financial results and established the timeline for its annual dividend and auditor transition.
Why it mattersThe results indicate stagnant growth with low operating margins (4.1%), while the auditor change and related party transaction approvals are key governance items for the upcoming AGM.
Q1 Revenue: ₹16.39 crQ1 Net Profit: ₹0.23 crDividend Record Date: Sept 4, 2026Q1 Revenue vs TTM Revenue: 24.46%Auditor Term: 5 years
📅 Short termThe stock is likely to remain neutral as the earnings show no significant growth catalyst, though the dividend record date may provide minor support.
📈 Long termLimited structural change; the company continues to operate in a single segment (Ayurvedic medicines) with stable but low profitability.
⚠ Risk flags
- Material related party transactions with Sandu Brothers Private Limited
- Low operating profit margins (4.1%)
- Stagnant year-on-year revenue growth
Key Highlights
Revenue from operations for Q1 FY27 stood at ₹16.39 cr, representing ~24.5% of TTM revenue.
Net profit for the quarter was ₹0.23 cr, compared to ₹0.23 cr in the corresponding quarter of the previous year.
Record date for determining dividend eligibility is fixed as September 4, 2026.
Proposed appointment of M/s. Dave & Dave as Statutory Auditors for a 5-year term until 2031.
The 41st Annual General Meeting (AGM) is scheduled for September 11, 2026.
👀 What to Watch
Investors should monitor the details of the 'Material Related Party Transactions' with Sandu Brothers Private Limited which are up for shareholder approval at the AGM.
Sandu Pharma Q1 Net Profit at ₹0.23 Cr; Sets Sept 4 as Record Date for Dividend
Sandu Pharmaceuticals reported a flat year-on-year performance for Q1 FY27, with revenue from operations at ₹16.39 Cr compared to ₹16.70 Cr in the previous year. Net profit remained stable at ₹0.23 Cr, while EPS improved slightly to ₹0.37 from ₹0.23. The board has fixed September 4, 2026, as the record date for the proposed FY26 dividend. Additionally, the company has proposed the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term.
Confidence: HIGH
What changedThe company has released its Q1 FY27 financial results and finalized the schedule for its 41st Annual General Meeting and dividend record date.
Why it mattersFor a micro-cap company with a ₹38 Cr market cap, maintaining stable profitability and consistent dividend timelines is key for investor confidence, though margins remain thin at 4.1%.
Q1 Revenue: ₹16.39 CrQ1 Net Profit: ₹0.23 CrRecord Date: September 4, 2026Revenue vs TTM Revenue: 24.46%Operating Profit Margin: 4.1%
📅 Short termThe stock may see limited movement given the flat earnings, though the dividend record date might provide minor support.
📈 Long termThe company shows stable but low-growth performance; long-term value depends on margin expansion beyond the current 4% levels.
⚠ Risk flags
- Material related-party transactions with promoter-linked entities
- Micro-cap liquidity risk
- Low operating margins
Key Highlights
Q1 FY27 revenue from operations stood at ₹16.39 Cr, contributing approximately 24.5% to TTM revenue.
Net profit for the quarter was ₹0.23 Cr, showing minimal change from ₹0.22 Cr in Q1 FY26.
Record date for determining dividend eligibility for FY26 is fixed as September 4, 2026.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term until 2031.
Approval sought for material related-party transactions with M/s. Sandu Brothers Private Limited at the upcoming AGM.
👀 What to Watch
Investors should note the September 4 record date for dividend eligibility and monitor the AGM outcome regarding the approval of material related-party transactions.
Sandu Pharma Q1 Revenue at ₹16.39 Cr; Sets Sept 4 as Dividend Record Date
Sandu Pharmaceuticals reported a flat performance for Q1 FY27, with revenue from operations at ₹16.39 crore compared to ₹16.70 crore in the same quarter last year. Net profit remained stable at ₹0.23 crore, matching the year-ago period. The board has fixed September 4, 2026, as the record date for the proposed FY26 dividend. Additionally, the company has recommended the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term and is seeking approval for material related-party transactions.
Confidence: HIGH
What changedThe company has released its first-quarter results for FY27 and finalized the administrative timeline for its AGM and dividend payout.
Why it mattersAs a micro-cap company with a ₹38 crore market cap, consistent profitability and governance (auditor change and related-party transactions) are key metrics for retail shareholders to track.
Revenue (Q1 FY27): ₹16.39 CrNet Profit (Q1 FY27): ₹0.23 CrDividend Record Date: Sept 4, 2026Q1 Revenue vs TTM Revenue: ~24.4%EPS (Q1 FY27): ₹0.37
📅 Short termNeutral. The stock may see minor interest leading up to the dividend record date in early September, but the flat earnings provide no immediate catalyst.
📈 Long termLimited. The company shows stagnant revenue growth and low operating margins (~4%), requiring a significant structural shift or expansion to re-rate.
⚠ Risk flags
- Material related-party transactions with Sandu Brothers Private Limited
- Low operating margins
- Micro-cap liquidity risk
Key Highlights
Revenue from operations for Q1 FY27 was ₹16.39 crore, representing a marginal 1.8% decline YoY.
Net profit for the quarter stood at ₹0.23 crore, identical to the ₹0.23 crore reported in Q1 FY26.
Record date for determining dividend eligibility for FY26 is fixed as September 4, 2026.
The 41st Annual General Meeting (AGM) is scheduled for September 11, 2026, via video conferencing.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term (2026-2031).
👀 What to Watch
Investors should monitor the upcoming AGM on September 11, 2026, specifically for the approval of material related-party transactions with Sandu Brothers Private Limited and the company's ability to scale its low operating margins.
Rs 16.39 Cr Revenue: Sandu Pharmaceuticals Q1 FY27 Results Flat YoY; New Auditor Appointed
Sandu Pharmaceuticals reported a marginal revenue decline of 1.8% YoY to Rs 16.39 Cr for the quarter ended June 30, 2026. Net profit remained stagnant at Rs 0.23 Cr, mirroring the performance of the same quarter last year, though it recovered from a low of Rs 0.02 Cr in the preceding March quarter. The company has fixed September 4, 2026, as the record date for its FY26 dividend. A significant governance update includes the proposed appointment of M/s. Dave & Dave as statutory auditors for a five-year term.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results and initiated a transition to a new statutory auditor, M/s. Dave & Dave, following the completion of the previous auditor's term.
Why it mattersFor a micro-cap company with a Rs 38 Cr market cap, stagnant revenue and thin margins (PBT of Rs 0.36 Cr) leave little room for error; the auditor change is a key governance event.
Revenue (Q1 FY27): Rs 16.39 CrNet Profit (Q1 FY27): Rs 0.23 CrRevenue vs TTM Revenue: 24.46%PBT Margin: 2.20%Dividend Record Date: 04-Sep-2026
📅 Short termThe stock is likely to remain neutral as the results show no significant growth or margin expansion to trigger a re-rating.
📈 Long termLimited structural change; the company continues to operate in a single segment (Ayurvedic Medicines) with stagnant annual revenue and low ROCE (5.5%).
⚠ Risk flags
- Very low operating margins
- Material related party transactions with promoter-linked entities
- Micro-cap liquidity risk
Key Highlights
Revenue from operations stood at Rs 16.39 Cr, down 1.8% from Rs 16.70 Cr in Q1 FY26.
Net profit for the quarter was Rs 0.23 Cr, representing a thin net margin of 1.4%.
Total expenses were slightly reduced to Rs 16.05 Cr from Rs 16.38 Cr in the year-ago period.
Record date for the FY26 dividend is set for September 4, 2026, with the AGM scheduled for September 11, 2026.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term until 2031.
👀 What to Watch
Investors should monitor the upcoming AGM for details on 'Material Related Party Transactions' with Sandu Brothers Private Limited and observe if the new auditor appointment leads to changes in financial reporting disclosures.
Sandu Pharmaceuticals Q1 PAT at ₹0.23 Cr; Dividend Record Date Set for Sept 4
Sandu Pharmaceuticals reported a flat performance for Q1 FY27, with a net profit of ₹0.23 Cr, nearly identical to the ₹0.22 Cr reported in the same quarter last year. Revenue from operations declined marginally by 1.8% YoY to ₹16.39 Cr. The company has fixed September 4, 2026, as the record date for its FY26 dividend. Additionally, the board has proposed the appointment of M/s. Dave & Dave as new statutory auditors for a five-year term and is seeking approval for material related-party transactions.
Confidence: HIGH
What changedThe company has released its first-quarter results for FY27 and established the timeline for its annual general meeting and dividend distribution.
Why it mattersThe results indicate a period of stagnant growth and tight margins (OPM remains low), which is critical for a micro-cap company with a ₹38 Cr market capitalization.
Q1 Revenue: ₹16.39 CrQ1 Net Profit: ₹0.23 CrYoY Revenue Growth: -1.8%Dividend Record Date: September 4, 2026Auditor Appointment Term: 5 Years
📅 Short termThe stock is likely to remain neutral in the short term as the earnings show no significant growth catalyst, though the dividend record date may provide minor support.
📈 Long termLimited structural significance; the company continues to operate at a small scale with low profitability and high reliance on related-party entities.
⚠ Risk flags
- Stagnant revenue growth
- Material related-party transactions with Sandu Brothers Private Limited
- Very thin net profit margins
Key Highlights
Revenue from operations for Q1 FY27 stood at ₹16.39 Cr, compared to ₹16.70 Cr in Q1 FY26.
Net profit for the quarter remained stagnant at ₹0.23 Cr (₹22.84 lakhs).
Record date for the FY26 dividend is fixed for September 4, 2026, with the AGM scheduled for September 11, 2026.
Proposed appointment of M/s. Dave & Dave, Chartered Accountants, as Statutory Auditors for a 5-year term until 2031.
Total expenses for the quarter were ₹16.05 Cr, accounting for 97.8% of total income.
👀 What to Watch
Investors should monitor the upcoming AGM on September 11, 2026, specifically for the approval of material related-party transactions with Sandu Brothers Private Limited and the transition to new auditors.
Sandu Pharmaceuticals Q1 Net Profit at ₹0.23 Cr; Dividend Record Date Set for Sept 4
Sandu Pharmaceuticals reported a flat year-on-year performance for Q1 FY27, with revenue from operations at ₹16.39 Cr compared to ₹16.70 Cr in the same period last year. Net profit remained stable at ₹0.23 Cr, showing a recovery from the ₹0.02 Cr reported in the preceding quarter (March 2026). The board has fixed September 4, 2026, as the record date for the proposed FY26 dividend. Additionally, the company is seeking shareholder approval for material related party transactions and the appointment of new statutory auditors for a five-year term.
Confidence: HIGH
What changedThe company has released its first-quarter results for FY27 and scheduled its 41st Annual General Meeting along with dividend timelines.
Why it mattersThe results indicate a stagnant growth profile with stable but low margins, while the auditor change and related party transaction approvals are key governance items for the upcoming AGM.
Revenue (Q1 FY27): ₹16.39 CrNet Profit (Q1 FY27): ₹0.23 CrRevenue vs TTM Revenue: 24.46%Dividend Record Date: September 4, 2026Auditor Appointment Term: 5 years
📅 Short termThe stock is likely to remain range-bound given the flat earnings performance and small-cap nature of the company.
📈 Long termLimited structural change is evident; the company continues to operate with low margins (OPM ~4%) and stagnant revenue growth.
⚠ Risk flags
- Material related party transactions with Sandu Brothers Private Limited
- Low operating margins
- Stagnant year-on-year revenue growth
Key Highlights
Revenue from operations for Q1 FY27 stood at ₹16.39 Cr, a marginal decline of 1.8% YoY.
Net profit for the quarter was ₹0.23 Cr, nearly identical to the ₹0.22 Cr reported in Q1 FY26.
Record date for determining dividend eligibility is fixed as September 4, 2026.
Proposed appointment of M/s. Dave & Dave as Statutory Auditors for a 5-year term until 2031.
Total Comprehensive Income for the period was ₹0.38 Cr, supported by fair value changes in investments.
👀 What to Watch
Investors should monitor the upcoming AGM on September 11, 2026, specifically for the approval of material related party transactions with Sandu Brothers Private Limited.
